Proleukin.  Aldesleukin for Injection




Information for Healthcare Professionals

Read Patient Stories


Facts About Kidney Cancer

Kidney cancer currently affects more than 36,000 people in the United States. Although kidney cancer was first reported in 1826, scientists have not yet determined its cause. Kidney cancer occurs in almost twice as many men as women, and most often develops after the age of 40. However, the disease has been seen in children as young as six months.

Kidney Cancer Risk Factors

People are at a higher risk of developing cancer if they have certain characteristics called risk factors. A risk factor is any trait or behavior that increases the chance of developing a disease. Some of the risk factors for kidney cancer include:

Family History: People with a family history of kidney cancer are nearly four times more likely to develop the disease.

Von Hippel-Lindau (VHL) syndrome: VHL is a very rare illness that runs in some families. People with VHL are predisposed to develop renal cell carcinoma. They may also develop cancers of the brain, spinal cord, pancreas, adrenal gland, and eye. Through genetic testing, the VHL gene mutation can now be detected.

Smoking: Cigarette smoking may account for as much as one fourth of all cases and is a major risk factor for kidney cancer. Cigar smoking may also increase risk.

Obesity: Research shows that obesity may increase the chance of developing kidney cancer, particularly in women.

Hemodialysis: kidney cancer is more common among patients receiving long-term hemodialysis. Hemodialysis is performed on patients whose kidneys function inadequately. The dialysis machine acts as an artificial kidney and is used to clear the blood in the way that a healthy, functioning kidney normally would.

Occupation: Certain types of occupations appear to increase the risk for kidney cancer, especially if the job requires contact with certain chemicals or substances. For example, iron- and steelworkers who are exposed to coke ovens, and workers consistently exposed to asbestos or cadmium may have a higher risk for kidney cancer.



PROLEUKIN Learning Center


PROLEUKIN® Learning Center
Explore the possibilities. To learn more about PROLEUKIN therapy and see if PROLEUKIN therapy is the appropriate treatment for your metastatic melanoma or metastatic kidney cancer, visit the PROLEUKIN Learning Center.



Treatment Center Finder

Treatment Center Regions

“Everyone with metastatic melanoma or metastatic renal cell carcinoma should find out if they are a candidate for PROLEUKIN therapy.”
Dr. Lee Riley, Medical Director, St. Luke’s Cancer Center, Bethlehem, PA.

Click here to find a PROLEUKIN treatment center nearest to your home.




Stay In Touch


> Submit


PROLEUKIN Product Information Line 1-866-9PROLEUKIN
This site intended for U.S. residents only. ©2008 Novartis Pharmaceuticals Corporation.



PROLEUKIN® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma.

Important Safety Information

Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should be used in patients with a normal thallium stress test and a normal pulmonary function test who have a history of cardiac or pulmonary disease.

PROLEUKIN® should be administered in a hospital setting under the supervision of a qualified physician experienced in the use of anticancer agents. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.

PROLEUKIN® administration has been associated with capillary leak syndrome (CLS) which is characterized by a loss of vascular tone, and extravasation of plasma proteins and fluid into the extravascular space. CLS results in hypotension and reduced organ perfusion which may be severe and can result in death. CLS may be associated with cardiac arrhythmias (supraventricular and ventricular), angina, myocardial infarction, respiratory insufficiency requiring intubation, gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental status changes.

PROLEUKIN® treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of PROLEUKIN® therapy. Patients with indwelling central lines are particularly at risk for infection with gram positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin, or vancomycin has been associated with a reduced incidence of staphylococcal infections.

PROLEUKIN® administration should be withheld in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.

Please see complete prescribing information, including box warning.

The content contained in this website is not intended to be a substitute for professional medical advice related to any topic discussed. Patients are urged to consult with their treating physicians or other professionals. Never disregard professional,medical or legal advice or delay seeking such advice because of something you have read on this website.


PROLEUKIN.com Home  |  What is PROLEUKIN & how does it work?  |  Metastatic Melanoma
Metastatic Kidney Cancer  |  PROLEUKIN Treatment Centers
Additional Resources and Links  |  Stay in Touch  |  Prescribing Information
Important Safety Information  |  INFORMATION FOR HEALTHCARE PROFESSIONALS

Contact Us  |  Site Guide  |  Site Map
Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement.
Copyright ©2008
Novartis Pharmaceuticals Corporation. All rights reserved.